Clinical trial
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
NCT00301873 · Duke University, Other · Completed
Key facts
| NCT number | NCT00301873 |
|---|---|
| Title | Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma |
| Official title | Phase II Study of Zometa (Zoledronic Acid) to Prevent Osteoporosis in Patients With Brain Tumors |
| Lead sponsor | Duke University, Other |
| Collaborators | Novartis Industry National Institute of Neurological Disorders and Stroke (NINDS) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies |
| Intervention type | Drug |
| Interventions | IV Zometa |
| Enrollment | 60 |
| Start date | May 1, 2006 |
| Primary completion | Feb 1, 2011 |
| Completion | Sep 1, 2012 |
| First posted | Mar 13, 2006 |
| Last update posted | Feb 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: